Clinical Study
Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
Figure 2
3-year overall survival between BioRT and SD-CCRT group. 3-year OS is 78.5% in SD-CCRT group versus 70.9% in BioRT group ().
